SCHEMBL318474

SCHEMBL318474

OC1=C(O)COC=C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7829463 0.59
SCHEMBL20787073 0.57
SCHEMBL10595589 0.56
SCHEMBL11268963 0.56
SCHEMBL1876497 0.55
SCHEMBL655807 0.54
SCHEMBL655806 0.54
SCHEMBL16504067 0.53
SCHEMBL11395526 0.53
SCHEMBL941967 0.51

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0580763-B1 COMPOSITIONS AND METHODS FOR ENDOTHELIAL BINDING UNIV LELAND STANFORD JUNIOR (US) 2006-09-06 EP claimed
US-20250339541-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-11-06 US disclosed
US-20250213699-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2025-07-03 US disclosed
US-12290568-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2025-05-06 US disclosed
US-12280116-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2025-04-22 US disclosed
US-20240424108-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-12-26 US disclosed
US-20240307546-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-09-19 US disclosed
US-12076408-B2 ASGPR-binding compounds for the degradation of extracellular proteins AVILAR THERAPEUTICS, INC. (US) 2024-09-03 US disclosed
US-20240245785-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-07-25 US disclosed
US-20240072809-A1 ASGPR-BINDING COMPOUNDS FOR THE DEGRADATION OF EXTRACELLULAR PROTEINS AVILAR THERAPEUTICS, INC. (US) 2024-02-29 US disclosed
US-20040002538-A1 Drug screening; forming libraries; solid phase biosynthesis PRESIDIO PHARMACEUTICALS, INC. 2004-01-01 US disclosed
WO-2003097628-A1 4-THIO COUMARINS VIVOQUEST, INC. (US) 2003-11-27 WO disclosed
US-20020068758-A1 Novel orally active iron (III) chelators BTG INTERNATIONAL LIMITED. 2002-06-06 US disclosed
US-6391857-B1 USING SELECTINS; ANTIINFLAMMATORY AGENTS STANFORD UNIVERSITY 2002-05-21 US disclosed
US-6387884-B1 MODULATE BINDING OF LEUKOCYTE TO ENDOTHELIAL CELLS; ANTIINFLAMMATORY AGENTS STANFORD UNIVERSITY 2002-05-14 US disclosed
CN-1280572-A Inhibiting platelet derivative growth factor and/or quinoline and quinowoline compounds of P56lek tyrosinkinase RHONE POULENC RORER PHARMA (US) 2001-01-17 CN disclosed
CN-1253021-A Hydroxylated carboxylate or amide used as solubilizing agent BASF AG (DE) 2000-05-17 CN disclosed
EP-0580763-A1 COMPOSITIONS AND METHODS FOR ENDOTHELIAL BINDING THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1994-02-02 EP disclosed
WO-1992018610-A2 COMPOSITIONS AND METHODS FOR ENDOTHELIAL BINDING THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 1992-10-29 WO disclosed
US-4298727-A BACTERICIDAL ANTIBIOTICS ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYUKAI (JP) 1981-11-03 US disclosed